Patents by Inventor Michael Kriegler

Michael Kriegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant PR-3 and assays employing the same
    Patent number: 6599706
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Jan Tuttleman, Carl Perez, David A. Jewell, Kirston E. Koths
  • Recombinant PR-3 and compositions thereof
    Patent number: 6586222
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Infective protein delivery system
    Patent number: 6071512
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: June 6, 2000
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Method for detecting the presence of P-selectin
    Patent number: 6033667
    Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: March 7, 2000
    Assignee: Cytel Corporation
    Inventors: Robert W. Chesnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn
  • Compositions for the inhibition of TNF hormone formation and uses thereof
    Patent number: 5998378
    Abstract: Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kDProTNF, and methods for identifying compounds having the desired inhibitory activity are provided.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: December 7, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez, Robert F. Halenbeck, David A. Jewell, Kirston E. Koths
  • TNF deletion muteins
    Patent number: 5889156
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: March 30, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Recombinant host cells encoding TNF proteins
    Patent number: 5888814
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: March 30, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Human til cells expressing recombinant TNF prohormone
    Patent number: 5874077
    Abstract: Tumor Infiltrating Lymphocyte (TIL) cells transformed with exogenous DNA encoding tumor necrosis factor (TNF) prohormone variants are disclosed. Among such variants are the TNF .gamma. sig construct, which facilitates expression of the mature TNF polypeptide, and the noncleavable cytotoxic prohormone variants TNF.DELTA.(1.fwdarw.12) and TNF(1+12). The transformed TIL cells are useful in antitumor therapy.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 23, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Gene fusion encoding a hypersecretor protein
    Patent number: 5863797
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: January 26, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Infective protein delivery system
    Patent number: 5849586
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 15, 1998
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Assay method for screening for inhibitors of proTNF conversion
    Patent number: 5843693
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF.alpha.. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF.alpha. to its mature active form.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: December 1, 1998
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Antibodies to P-selectin and their uses
    Patent number: 5800815
    Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: September 1, 1998
    Assignee: Cytel Corporation
    Inventors: Robert W. Chestnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn
  • Antibody methods for the treatment of a hormone-mediated disease
    Patent number: 5702705
    Abstract: Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez
  • Assay method for the detection of 26kd TNF prohormone
    Patent number: 5686259
    Abstract: Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 11, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez
  • Cleavage site blocking antibody to prohormone proteins and uses thereof
    Patent number: 5677182
    Abstract: Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: October 14, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez
  • Retroviral vectors expressing tumor necrosis factor (TNF)
    Patent number: 5652130
    Abstract: A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: July 29, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Francis P. McCormick
  • Method for determining TNF
    Patent number: 5639593
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, AIDS and autoimmune diseases.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: June 17, 1997
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki
  • Retroviral vectors expressing cytokines
    Patent number: 5635399
    Abstract: A drug delivery virion which contains an expression system for the desired protein active ingredient packaged in an envelope derived from a retrovirus is especially useful in administering materials which need to cross cell membranes in order to serve their function.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Francis P. McCormick
  • Assay for determinig TNF or IL-1 convertase activity
    Patent number: 5545518
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, and autoimmune diseases.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: August 13, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki
  • Methods for the identification of cytokine convertase inhibitors
    Patent number: 5422425
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, and autoimmune diseases.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: June 6, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki